ISRCTN46127225已完成1 期
A Phase I, open-label, single-dose, single-period study to assess the mass balance recovery, metabolite profile and metabolite identification of [14C]AZD9833 after oral administration in healthy post-menopausal female subjects
AstraZeneca (Sweden)0 个研究点目标入组 6 人开始时间: 2022年5月5日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 6
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- Female
入选标准
- •1. Provision of signed and dated, written informed consent prior to any study-specific procedures
- •2. Aged between 50 to 70 years inclusive at the time of signing informed consent
- •3. Healthy post-menopausal females, defined as post-menopausal by fulfilling the following criterion:
- •3.1. Amenorrhoea for at least 12 months following cessation of all exogenous hormonal treatments and without an alternative medical or surgical cause and confirmed by an FSH result of =30 IU/l
- •4. Must be willing and able to communicate and participate in the whole study
- •5. Have a body mass index (BMI) between 19.0 to 35.0 kg/m², weigh at least 50 kg and no more than 100 kg inclusive as measured at screening.
- •6. Must have regular bowel movements (i.e. average stool production of =1 and =3 stools per day)
排除标准
- •1. History of any clinically significant disease or disorder which, in the opinion of the Investigator, may either put the volunteer at risk because of participation in the study, or influence the results or the volunteer’s ability to participate in the study
- •2. History or presence of GI, hepatic or renal disease, or any other condition known to interfere with absorption, distribution, metabolism, or excretion of drugs
- •3. Any clinically significant illness, medical/surgical procedure, or trauma within 4 weeks of the first administration of IMP
- •4. History of or ongoing clinically significant visual disturbances including but not limited to visual hallucinations, migraine with visual symptoms, blurred vision, frequent floaters/flashes associated with other symptoms such as dizziness
- •5. Any clinically significant abnormalities in clinical chemistry, haematology, or urinalysis results, at screening as judged by the Investigator.
- •6. Any clinically significant abnormal findings in vital signs at screening as judged by the Investigator, including systolic BP <100 mmHg, diastolic BP <50 mmHg or heart rate <50 bpm. Vital signs outside these limits can be repeated once for confirmation
- •7. Any clinically significant abnormalities on 12-lead ECG at screening, as judged by the Investigator, including non-sinus rhythms, PR interval <120 msec or >220 msec, ventricular rate <50 bpm or >100 bpm, QRS interval >120 msec, or QTcF >470 msec as a mean of triplicate. ECGs can be repeated once in triplicate if parameters are outside these limits for confirmation
- •8. Evidence of renal impairment at screening, as indicated by an estimated creatinine clearance (CLcr) of <60 ml/min/1.73m² using the Cockcroft-Gault equation
- •9. Any positive result on screening for serum hepatitis B surface antigen (HBsAg), hepatitis C antibody (HCV Ab), and human immunodeficiency virus (HIV) 1 and 2 antibodies
- •10. Has received another new chemical entity (defined as a compound which has not been approved for marketing) within 4 weeks prior to Day 1, or less than 5 elimination half-lives + 6 days prior to Day 1, whichever is longer. Note: subjects consented and screened, but not administered IMP in this study or a previous Phase I study, are not excluded
- •11. Plasma donation within 1 month of screening or any blood donation/loss more than 500 ml during the 3 months prior to screening
- •12. History of severe allergy/hypersensitivity or ongoing allergy/hypersensitivity, as judged by the Investigator or history of hypersensitivity to drugs with a similar chemical structure or class to AZD9833. Hay fever is allowed unless it is active
- •13. Any known or suspected hypersensitivity or contraindication to the components of the study drug, AZD9833, judged to be clinically relevant by the investigator
- •14. Current smokers or those who have smoked or used nicotine products (including e-cigarettes) within the 3 months prior to screening
- •15. A confirmed breath carbon monoxide reading of greater than 10 ppm at screening or admission
- •16. Positive screen for drugs of abuse at screening or on each admission to the study centre
- •17. Regular alcohol consumption >14 units per week (1 unit = ½ pint beer, or a 25 mL shot of 40% spirit, 1.5 to 2
研究者
相似试验
进行中（未招募）
1 期
An open-label mass balance study of [14C]NST-6179 in healthy male subjectsIntestinal failure associated liver disease (IFALD), also referred to as parenteral nutrition (PN) associated liver disease, and other potential indications.Digestive SystemISRCTN12367117orthSea Therapeutics B.V.8
进行中（未招募）
1 期
A study to evaluate the effect of itraconazole and carbamazepine on the processing of fenebrutinib by the body in healthy participantsHealthy volunteersISRCTN12005942Genentech32
已完成
1 期
A study to investigate the effects of food and administration of different forms of mavodelpar on the safety and concentration of mavodelpar in the bloodHealthy VolunteersISRCTN85791974Reneo Pharma Ltd (United Kingdom)32
招募中
1 期
Phase 1 Pediatric Pharmacokinetics/Pharmacodynamics (PK/PD) StudyCTRI/2018/09/015649DAIICHI SANKYO INC
已完成
1 期
A study to evaluate the effects of multiple doses of itraconazole and carbamazepine on processing of giredestrant by the body in healthy female participantsHealthy female participantsISRCTN16366416Genentech33